LexaGene Announces its Second Hemp-Cannabis Reference Testing Laboratory as a Beta Test Web-site


BEVERLY, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF TSX-V: LXG) (“LexaGene”) or the (“Company”), a biotechnology organization that develops genetic analyzers for fast pathogen detection and other molecular markers, announced right now plans to location its LX Analyzer beta unit into ProVerde Laboratories, Inc. (“ProVerde”), a single of the biggest hempcannabis testing reference laboratories in Massachusetts.

ProVerde Laboratories is a single of 3 independent laboratories accredited by the state of Massachusetts to test hemp and cannabis goods for contaminants such as pesticides and pathogens like bacteria, mold, or other unsafe microorganisms. Their testing capabilities are described in this video

ProVerde at present cultures samples overnight, followed by processing measures that involve applying an automated single-target immunoassay analyzer to determine pathogenic organisms as nicely as beginning a second culture to enumerate indicator species.  The procedure nominally requires three days, and ProVerde is seeking for more rapidly turn-about instances.  For this explanation, ProVerde is interested in testing LexaGene’s analyzer, which is made to screen for various pathogenic organisms at after and offer quantitation of indicator organisms in just 1 hour.  For the beta test trial, which is scheduled to start out subsequent week, ProVerde will use LexaGene’s genetic analyzer to detect and quantify pathogenic E. coli, Salmonella, and the toxic fungus, Aspergillus niger

“In the United States, the requirements for hemp and cannabis testing are at present all more than the map, as diverse states have diverse regulations.  ProVerde is active and vocal in advertising the rewards of uniform testing needs across all the states,” stated Dr. Christopher Hudalla, ProVerde’s Founder and Chief Scientific Officer. “Over the previous a number of years, we have worked with a quantity of revolutionary firms to enable them create, refine and validate their gear, processes and goods for the cannabis and hemp testing markets.  It is fascinating to function with LexaGene and their new fast detection platform which has the possible to make an influence on the testing demands of these industries.”

As the use of cannabis and hemp goods for medicinal purposes increases, so does the chance for LexaGene to offer its open-access instrument for use in testing laboratories to allow screening for pathogens that influence human overall health. 

“This is now our second beta placement in a hempcannabis testing reference laboratory,” stated Dr. Jack Regan, LexaGene’s CEO and Founder. “We strongly think the LX technologies will be revolutionary for the hemp and cannabis business as it will enable avoid the spread of illness and can be utilized to make certain safer goods for consumption.”

To be added to the LexaGene e mail distribution list, please subscribe on the Firm web page.

About LexaGene Holdings Inc.
LexaGene is a biotechnology organization that develops genetic analyzers for pathogen detection and other molecular markers for on-web site fast testing in veterinary diagnostics, meals security and for use in open-access markets such as clinical analysis, agricultural testing and biodefense. Finish-customers basically need to have to gather a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID, and press ‘go’. The LX Analyzer delivers exceptional sensitivity, specificity, and breadth of detection and can procedure various samples at a time, in an on-demand style, returning benefits in about 1 hour. The special open-access function is made for custom testing so that finish-customers can load their personal true-time PCR assays onto the instrument to target any genetic target of interest.

About ProVerde Laboratories

ProVerde Laboratories, Inc. is a Massachusetts primarily based laboratory supplying analytical testing and consulting solutions for a wide range of markets like the marijuana and hemp segment. Offered solutions make use of top-edge technologies to yield the most trustworthy analytical benefits out there, when sustaining an environmentally friendly, green method.

Media Contacts
Nicole Ridgedale
Director of Corporate Advertising and marketing, LexaGene
800.215.1824 ext 206
[email protected]

Investor Relations
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
[email protected]

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither authorized nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Solutions Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts duty for the adequacy or accuracy of this release.

This news release includes forward-seeking data, which entails recognized and unknown dangers, uncertainties and other things that may perhaps bring about actual events to differ materially from existing expectation. Essential things — like the availability of funds, the benefits of financing efforts, the results of technologies improvement efforts, the price to procure essential components, efficiency of the instrument, market place acceptance of the technologies, regulatory acceptance, and licensing difficulties — that could bring about actual benefits to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to location undue reliance on these forward-seeking statements, which speak only as of the date of this press release. The organization disclaims any intention or obligation, except to the extent necessary by law, to update or revise any forward-seeking statements, no matter if as a outcome of new data, future events or otherwise.


Latest posts